February brought a one-two punch in the GLP-1 access fight: regulators and Novo Nordisk pressed harder against compounded semaglutide, while a new direct-to-consumer channel undercut prices on the FDA-approved versions.
In February 2026, the FDA and Novo Nordisk escalated action against compounded semaglutide, including a Novo lawsuit against a telehealth company over compounded products, while a new direct-to-consumer channel launched lower-cost access to FDA-approved GLP-1s. Together they widened the gap between authorized and compounded options.
The fight over how Americans get GLP-1 medicines intensified in February on two fronts at once.
On one side, pressure on compounded copies; on the other, cheaper access to the approved drugs.
Early in the month, regulators reiterated that compounded copies of commercially available GLP-1s are generally not permitted now that shortages are resolved, and Novo Nordisk escalated enforcement, including a lawsuit filed against a major telehealth company alleging patent infringement tied to compounded semaglutide made with what it described as non-authentic active ingredient. Coverage also noted FDA warning activity directed at sellers marketing compounded semaglutide and tirzepatide.
At the same time, a new direct-to-consumer purchasing channel debuted offering FDA-approved GLP-1s at lower advertised prices, with reported figures such as semaglutide tablets in the low hundreds of dollars versus four-figure list prices, and discounted injectable semaglutide and tirzepatide. The combined effect pushed consumers toward authorized products by both restricting compounded supply and lowering the price of approved options.
For consumers, February reinforced a practical rule: the safest GLP-1 is an FDA-approved product obtained through a licensed prescriber, and the price gap that once drove people to compounded versions is narrowing. Claims and prices change quickly, so verifying that a seller offers genuine, approved medication and operates legally matters more than chasing the lowest advertised number.
What to watch includes how the litigation resolves, whether the new lower direct-buy prices persist, and whether further FDA warning activity follows. The broader trajectory points toward consolidating demand around authorized products as both enforcement and pricing move in that direction. Because terms and prices in this space change quickly, the durable habit is to confirm that any seller supplies genuine, FDA-approved medication through a lawful, licensed pathway before money or health is on the line.